Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma

• Published in: Targeted oncology 2019-10, Vol.14 (5), p.563-575
• Main Authors: Park, Steven I., Lin, Carolina P., Ren, Natalie, Angus, Steven P., Dittmer, Dirk P., Foote, Michael, Parton, Trevor, Bhatt, Aadra P., Fedoriw, Yuri D., Roth, Daniel P., Cann, Marissa L., Johnson, Gary L., Damania, Blossom
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Apoptosis; Aurora Kinase A - antagonists & inhibitors; Azepines - pharmacology; Biomedicine; Cell Cycle; Cell Line, Tumor; Chemotherapy; Cyclophosphamide - pharmacology; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lymphoma; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - genetics; Medicine; Medicine & Public Health; Mice; Mice, Nude; Mice, Transgenic; Mutation - genetics; Oncology; Original Research Article; Proto-Oncogene Proteins c-myc - genetics; Pyrimidines - pharmacology; Targeted cancer therapy; Tumors
• ISSN: 1776-2596; 1776-260X
• DOI: 10.1007/s11523-019-00662-4

Background Aberrant Myc expression plays a critical role in various tumors, including non-Hodgkin lymphoma (NHL). Myc-positive lymphoma is clinically aggressive, more resistant to chemotherapy, and associated with high mortality. Objective The current study aimed to show inhibition of aurora A kinase (AURKA) may overcome resistance to chemotherapy and improve outcomes in Myc-overexpressing lymphoma. Methods Myc-overexpressing lymphoma cell lines were evaluated by trypan blue, annexin V/propidium iodide staining, and western blotting for cytotoxicity, cell cycle, apoptosis, and Myc-associated protein expression, respectively, in the presence of cyclophosphamide with or without MLN8237, an AURKA inhibitor. Immunofluorescence for apoptosis-inducing factor (AIF) and acridine orange staining were used to analyze levels of autophagy. EµMyc genetically modified mouse model and xenograft models bearing Myc-overexpressing lymphoma cells were used to determine the efficacy of cyclophosphamide, MLN8237, or the combination in chemosensitive and chemoresistant tumors. Results In our in vitro experiments using chemoresistant lymphoma cells, MLN8237 and cyclophosphamide showed synergistic effects. Mice bearing lymphoma xenograft had rapid disease progression with median survival of ~ 35 days when treated with cyclophosphamide alone. In contrast, the combination of cyclophosphamide and MLN8237 induced complete tumor regression in all mice, which led to improvement in survival compared with the single agent control ( p  = 0.022). Kinome analysis of tumors treated with MLN8237 showed global suppression of various kinases. Conclusion Our data demonstrate that AURKA inhibition induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma. The combination of MLN8237 and conventional chemotherapy showed promising safety and anti-tumor activities in preclinical models of Myc-positive NHL.